Interference of canakinumab with commercial IL-1 β ELISAs.

Interference of canakinumab with commercial IL-1β ELISAs. Clin Immunol. 2019 May 13;: Authors: Linge M, Hedrich CM, Rösen-Wolff A, Winkler S PMID: 31096037 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31096037?dopt=Abstract

Source: Clinical Immunology - May 12, 2019 Category: Allergy & Immunology Authors: Linge M, Hedrich CM, Rösen-Wolff A, Winkler S Tags: Clin Immunol Source Type: research

More News: Allergy & Immunology | Science